Estrogen Receptor Antagonist in Patients With Pulmonary Arterial Hypertension

Pulmonary Arterial Hypertension Clinical Trial

— ERA-PAH  

Official title:

Estrogen Receptor Antagonist in Patients With Pulmonary Arterial Hypertension

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02911844
• Other study ID #: 824861
• Status: Completed
• Phase: Phase 2
• Start date: April 10, 2017
• Est. completion date: December 5, 2018

Study information

• Verified date: December 2019
• Source: University of Pennsylvania
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The main purpose of this clinical trial is to examine the feasibility and effects of fulvestrant in post-menopausal women with pulmonary arterial hypertension (PAH). The study will evaluate how well the drug is tolerated. The study will evaluate changes in circulating hematopoietic progenitor cells, plasma hormone levels, NT-proBNP, and other plasma biomarkers after the administration of fulvestrant. Changes in tricuspid annular plane systolic excursion, stroke volume index, right ventricular fractional area change, and other echo parameters after fulvestrant administration will be evaluated as well as changes in distance walked in six minutes.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 5
• Est. completion date: December 5, 2018
• Est. primary completion date: December 5, 2018
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Previous documentation of mean pulmonary artery pressure > 25 mm Hg with a pulmonary capillary wedge pressure (or left ventricular end-diastolic pressure) < 16 mm Hg and pulmonary vascular resistance > 3 WU at any time before study entry.

• Diagnosis of PAH which is idiopathic, heritable, drug- or toxin-induced, or associated with connective tissue disease, congenital heart disease, portal hypertension, or HIV infection.

• Most recent pulmonary function tests with FEV1/FVC >50% AND either a) total lung capacity > 70% predicted or b) total lung capacity between 60% and 70% predicted with no more than mild interstitial lung disease on computerized tomography scan of the chest.

• Female, post-menopausal state, defined as:

• > 50 years old and a) have not menstruated during the preceding 12 months or b) have follicle-stimulating hormone (FSH) levels > 40 IU/L or

• < 50 years and FSH > 40 IU/L or

• having had a bilateral oophorectomy.

• Informed consent.

Exclusion Criteria:

• Age < 18.

• Treatment with estrogen or anti-hormone therapy (tamoxifen, anastrozole, etc.)

• WHO Class IV functional status.

• History of breast cancer.

• Clinically significant untreated sleep apnea.

• Left-sided valvular disease (more than moderate mitral valve stenosis or insufficiency or aortic stenosis or insufficiency), pulmonary artery or valve stenosis, or ejection fraction < 45% on echocardiography.

• Initiation of PAH therapy (prostacyclin analogues or receptor agonists, endothelin-1 receptor antagonists, phosphodiesterase-5 inhibitors, soluble guanylate cyclase stimulators) within three months of enrollment; the dose must be stable for at least 3 months prior to Baseline Visit. PAH therapy which is stopped and then restarted or has dose changes which are not related to initiation and uptitration will be allowed within 3 months prior to the Baseline Visit.

• Hormone therapy.

• Use of warfarin or other anticoagulant (use of aspirin is permitted).

• Platelet count <100,000.

• Renal failure (creatinine >/= 2.0).

• Child-Pugh Class C cirrhosis.

• Current or recent (< 6 months) chronic heavy alcohol consumption.

• Current use of another investigational drug (non-FDA approved) for PAH.

Related Conditions & MeSH terms

• Familial Primary Pulmonary Hypertension
• Hypertension
• Pulmonary Arterial Hypertension

Intervention

Drug:
• Fulvestrant
Fulvestrant 500 mg administered intramuscularly into the buttocks slowly as two 5 mL injections, one in each buttock, on days 0, 14, 28 and 56. Fulvestrant 250 mg (one 5 mL injection) will be used in patients with Child-Pugh Class B liver disease.

Locations

Country	Name	City	State
United States	University of Pennsylvania	Philadelphia	Pennsylvania

Sponsors (1)

Lead Sponsor	Collaborator
University of Pennsylvania

Country where clinical trial is conducted

United States, 

References & Publications (1)

Kawut SM, Pinder D, Al-Naamani N, McCormick A, Palevsky HI, Fritz J, Smith KA, Mazurek JA, Doyle MF, MacLean MR, DeMichele A, Mankoff DA. Fulvestrant for the Treatment of Pulmonary Arterial Hypertension. Ann Am Thorac Soc. 2019 Nov;16(11):1456-1459. doi: — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change From Baseline of Plasma Estradiol Levels	Plasma estradiol levels are obtained and measured from blood samples collected from each participant.; Difference in change from baseline to 9 weeks in plasma estradiol levels	Baseline to 9 weeks
Primary	Change From Baseline of Tricuspid Annular Plane Systolic Excursion (TAPSE)	Measure obtained from echocardiogram completed on participants Difference in change from baseline to 9 weeks in TAPSE	Baseline to 9 weeks
Primary	Change From Baseline of Six Minute Walk Distance	Measure obtained from six minute walk test completed by participants Difference in change from baseline to 9 weeks in the six minute walk test distance	Baseline to 9 weeks
Primary	Change From Baseline of Plasma NT-proBNP Level	Plasma NT-proBNP levels are obtained and measured from blood samples collected from each participant.; Difference in change from baseline to 9 weeks in plasma NT-proBNP levels	Baseline to 9 weeks